Shionogi reaches primary endpoint for ensitrelvir
Positive results in COVID-19 therapy phase 3 trials show effectiveness against five symptoms
Read More
Tag: ensitrelvir
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
